Business
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions Pipeline advancements and global efforts remain on track Management to host conference call today, August 6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the second quarter ended June 30, 2025. “As we approach the two-year anniversary of the XDEMVY launch, we have delivered our strongest quarter to date with over $100 million in net sales and established XDEMVY as the standard of care for Demodex blepharitis,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “We now believe its peak potential is even greater than we initially expected at launch. With strong ongoing commercial execution, a differentiated pipeline, and a focus on category creation, we remain confident in our ability to drive sustained growth and position ourselves for long-term leadership in eye care.” Recent Business and Clinical Highlights XDEMVY is one of the fastest growing and best-selling launches in the prescription eye drop segment with Q2 results of: $102.7 million in net product sales.Approximately 91,000 bottles distributed to patients.More than 90% of commercial, Medicare and Medicaid lives covered.Approximately 45% gross-to-net discount. The Company’s action-oriented direct-to-consumer (DTC) advertising campaign meaningfully contributed to prescription growth, resulting from new patients and subsequent increase in Eye Care Professionals (ECPs) diagnosing Demodex blepharitis and writing prescriptions. Active consumer engagement on our XDEMVY.com website is up nearly 400% since the beginning of 2025.Consumer unaided awareness of XDEMVY has more than tripled since the beginning of the DTC campaign.More than 20,000 ECPs are now prescribing XDEMVY, a more than 30% increase since the beginning of 2025 and beyond the Company’s target list of approximately 15,000 ECPs. Clinical Development: the Company’s robust pipeline remains on track with plans to initiate: A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential...